Stock Market Reviews

Read and share opinions on ELTX (Elicio Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock marke

Latest News

• Elicio Therapeutics Reports Inducement Grants
  Dec 16, 2025
• Elicio Therapeutics (ELTX) Upgraded to Buy: Here's Why
  Dec 11, 2025
• Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer
  Nov 19, 2025
• Elicio Therapeutics: Q3 Earnings Snapshot
  Nov 13, 2025
• Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
  Sep 29, 2025
• Elicio Therapeutics Unveils Follow-up Data From Pancreatic Cancer Study, Share up Pre-Bell
  Aug 12, 2025
• Elicio Therapeutics: Q2 Earnings Snapshot
  Aug 7, 2025
• Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer
  Jun 17, 2025

ELTX News

• Elicio Therapeutics Reports Inducement Grants
  BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on December 15, 2025, Elicio granted an aggregate of 157,193 inducement stock options to three new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The induce
  Dec 16, 2025
• Elicio Therapeutics (ELTX) Upgraded to Buy: Here's Why
  Elicio Therapeutics (ELTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
  Dec 11, 2025
• Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial
  Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden immune responses to personalized tumor neoantigens not present in the targeted immunotherapy87% (13/15) of evaluated patients demonstrated induction of T cell responses to tumor neoantigens beyond mKRAS following ELI-002 7P therapyThe induction of non-mKRAS antigen-specific T cell responses supports the potential for ELI-002 7P to generate a broader, more adaptable, and personalized ant
  Dec 11, 2025
• Pancreatic Cancer Market Set to Expand During the Forecast Period (2025-2034) as Precision Medicine and Immunotherapy Transform Treatment Landscape | DelveInsight
  DelveInsight's Pancreatic Cancer Market Insights report includes a comprehensive understanding of current treatment practices, pancreatic cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).
  Dec 10, 2025
• Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer
  Strategic Hire Strengthens Late Phase and Commercial Readiness as Elicio Advances Lymph Node-Targeted Immunotherapy PipelineBOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Marc J. Wolfgang, M.S. as Chief Technology Officer (“CTO”). Mr. Wolfgang brings more than 30 years of biopharmaceut
  Nov 19, 2025
• Elicio Therapeutics: Q3 Earnings Snapshot
  BOSTON (AP) — Elicio Therapeutics, Inc. ELTX) on Thursday reported a loss of $10.1 million in its third quarter. On a per-share basis, the Boston-based company said it had a loss of 60 cents.
  Nov 13, 2025
• Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
  In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), fewer disease progressions and deaths than projected have been observed as of November 6, 2025. Based on 2:1 randomization with twice as many patients in the ELI-002 7P treatment arm compared to the observation arm, Elicio believes the lower-than-projected number of disease progressions and deaths may reflect a favorable impact on disease-free survival (“DFS”); event-driven p
  Nov 13, 2025
• KRAS Inhibitors Market to Witness Explosive Growth at a CAGR of 35% During the Forecast Period (2025–2034) Amid Expanding Therapeutic Landscape | DelveInsight
  The KRAS inhibitors market is expected to experience substantial growth, driven by rising cancer incidence, improved treatment access, and a robust pipeline including Olomorasib (Eli Lilly), MK-1084 (Merck/Taiho/Astex Pharmaceuticals), Divarasib (Roche), Daraxonrasib (Revoltuion Medicines), Onvansertib (Cardiff Oncology), ELI-002 (Elicio Therapeutics), and others across the 7MM. G12C is the most prevalent KRAS mutation in NSCLC, making it a key target of current therapies. Following the success
  Nov 12, 2025
• Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC
  SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapyELI-002 7P induced mKRAS-specific T cell responses in 99% of evaluable patients (89/90), demonstrating potent and consistent immune activationRobust immune responses were elicited across all seven mKRAS antigens, with >80% response rate to each individual KRAS mutation and 88% of patients generating
  Nov 7, 2025
• Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial
  ELI-002 7P demonstrated robust mKRAS-specific T cell responses across a broad range of HLA types, highlighting its potential for use among a diverse patient populationPatients treated with ELI-002 7P represented a diverse HLA repertoire including 1,132 unique types identified among 1,398 total HLA backgrounds in assessed patients99% (88/89) of patients assessed for HLA background induced mKRAS-specific T cell responses after treatment with ELI-002 7PInduction of mKRAS-specific T cell responses s
  Oct 27, 2025
• Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
  Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor (“CPI”) in the neoadjuvant settingTrial is anticipated to begin enrolling in H1’2026 BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the planned initiation of an investigator-initiated Phase 1 neoadjuvant study of
  Sep 29, 2025
• Elicio Therapeutics Reports Inducement Grants
  BOSTON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on September 15, 2025, Elicio granted an aggregate of 9,800 inducement stock options to two new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The induceme
  Sep 18, 2025
• Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial
  ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational vaccine immunotherapyRobust mKRAS-specific T cell responses were observed with an average of 145.3x increase over baseline (median 44.3x; range 2.13-1310x), consistent with prior ELI-002 Phase 1 trial resultsT cell responses included both mKRAS-specific CD4 and CD8 T cells in 85% of patients BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq:
  Sep 17, 2025
• Elicio’s peptide cancer vaccine shows survival benefit in Phase I trial
  The mKRAS-targeting cancer vaccine reduced the risk of death by 77% by activating the anti-tumour mechanisms of key immune cells.
  Aug 13, 2025
• Elicio Therapeutics Unveils Follow-up Data From Pancreatic Cancer Study, Share up Pre-Bell
  Elicio Therapeutics (ELTX) said Tuesday that data from its phase-1 study evaluating ELI-002 in patie
  Aug 12, 2025
• Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients
  At extended median follow-up of 19.7 months, median overall survival (“OS”) increased from 16.33 to 28.94 months Clinical efficacy correlated with the magnitude of T cell responses specific to mutant-KRAS (“mKRAS”) induced by ELI-00277% reduction in the risk of death and 88% reduction in the risk of relapse, associated with T cell responses above the threshold for anti-tumor efficacyELI-002 induced both CD4+ and CD8+ mKRAS-specific T cell responses in most patients, and evidence of antigen-sprea
  Aug 12, 2025
• Elicio Therapeutics: Q2 Earnings Snapshot
  BOSTON (AP) — Elicio Therapeutics, Inc. ELTX) on Thursday reported a loss of $10.6 million in its second quarter. On a per-share basis, the Boston-based company said it had a loss of 66 cents.
  Aug 7, 2025
• Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
  Recent positive recommendation by the Independent Data Monitoring Committee (“IDMC”) to continue ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications to final analysis Event-driven final analysis focused on disease-free survival (“DFS”) expected in Q4 2025 Secured $10 million financing in Q2 2025; Current cash position expected to support operations beyond anticipated AMPLIFY-7P Phase 2 final analysis BOSTON, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (
  Aug 7, 2025
• Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis
  The AMPLIFY-7P study of ELI-002 7P successfully passes event-driven interim analysis for efficacy, futility, and safety by the IDMC The Company views the IDMC’s positive recommendation as an indication that ELI-002 7P has shown preliminary signals of efficacy Final disease-free survival analysis is anticipated to occur in Q4 2025Elicio previously reached alignment with the FDA on key elements of the planned pivotal Phase 3 study designThe Company’s current cash runway extends into Q1 2026, past
  Aug 5, 2025
• Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy’ Ratings
  Three emerging biotech companies — Elicio Therapeutics, Cellectis, and Autolus Therapeutics — are attracting “Strong Buy” analyst ratings in 2025 as major clinical, regulatory, and commercial catalysts position them for standout growth in the cancer treatment market.
  Jul 28, 2025
• Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer
  BOSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it will host a virtual key opinion leader (“KOL”) event on Wednesday, June 25, 2025 at 2:00 PM ET to discuss the significant unmet need and current treatment landscape for mutant-KRAS (“mKRAS”) driven pancreatic ductal adenocarcinoma (“PDAC”), one of th
  Jun 17, 2025
• Elicio Therapeutics Secures $10 Million in Financing
  Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025. BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has entered a $10 million senior secured promissory note (the “Note”) with existing investor, GKCC, LLC (“Note Holder” or “GKCC”
  Jun 4, 2025
• Elicio Therapeutics: Q1 Earnings Snapshot
  BOSTON (AP) — Elicio Therapeutics, Inc. ELTX) on Tuesday reported a loss of $11.2 million in its first quarter. The Boston-based company said it had a loss of 87 cents per share.
  May 13, 2025
• Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates
  Interim analysis focused on disease-free survival (“DFS”) in randomized Phase 2 AMPLIFY-7P clinical trial expected in Q3 2025 Company has alignment with U.S. Food and Drug Administration (“FDA”) on key design elements of planned Phase 3 study of ELI-002 Current cash position expected to support operations beyond anticipated AMPLIFY-7P Phase 2 interim analysis BOSTON, May 13, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnolo
  May 13, 2025
• Here's Why Elicio Therapeutics (ELTX) Could be Great Choice for a Bottom Fisher
  Elicio Therapeutics (ELTX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
  May 1, 2025

ELTX Reviews

• CapitalHex

  Dec 30, 2025

  $ELTX Focusing on groundbreaking therapies, this organization is pioneering advancements in its field. The commitment to addressing unmet medical needs could position it as a significant contributor to future healthcare solutions, appealing to investors interested in the biotech sector.

  Buy

• LiquidityLord

  Dec 30, 2025

  $ELTX With a focus on novel therapeutic solutions, this organization is making strides in the biotech field. Their research and development efforts reflect a commitment to addressing unmet medical needs, potentially paving the way for groundbreaking advancements.

  Buy

• OptionOutlaw

  Dec 30, 2025

  $ELTX Innovation? More like stagnation. Better luck next time!

  Sell

• EquityAssault

  Dec 29, 2025

  $ELTX Therapeutics? More like therapeutic for your losses.

  Sell

• HODLWarrior

  Dec 29, 2025

  $ELTX This one’s got potential, ready to take off like a rocket!

  Buy

• ChartCrusher

  Dec 28, 2025

  $ELTX Like a fading star, it’s losing its shine fast.

  Sell

• ShortAndProud

  Dec 28, 2025

  $ELTX This crew's making moves in the lab, watch out.

  Buy

• YieldSlasher

  Dec 27, 2025

  $ELTX Good luck finding magic potions here.

  Sell

• AlphaRogue

  Dec 27, 2025

  $ELTX This is the underdog you root for in movies – working hard and ready to surprise everyone with a plot twist!

  Buy

• CashWraith

  Dec 27, 2025

  $ELTX With the clock ticking on drug approvals, this biotech firm is in a race against time. If they miss the mark, the repercussions could be devastating!

  Sell

• RiskProtocol

  Dec 26, 2025

  $ELTX In the ever-shifting landscape of biotech, the stakes are sky-high! Each development could mean breakthroughs or busts, and the suspense is palpable.

  Buy

• BullishVanguard

  Dec 25, 2025

  $ELTX This stock is like a bad therapy session - full of disappointment.

  Sell

• TradeHex

  Dec 25, 2025

  $ELTX This biotech firm's research initiatives in novel therapies are promising, with potential groundbreaking treatments on the horizon. Their commitment to innovation and addressing unmet medical needs could yield significant advancements.

  Buy

• AlphaStriker

  Dec 24, 2025

  $ELTX Chasing dreams in a field that’s mostly just a nightmare.

  Sell

• TradeFrenzy

  Dec 23, 2025

  $ELTX A therapeutic pipe dream that won't deliver.

  Sell

• LiquidLegend

  Dec 23, 2025

  $ELTX This company's future is brighter than my phone screen at midnight – and that’s saying something!

  Buy

• ChartFang

  Dec 23, 2025

  $ELTX With a focus on transformative therapies, this biotech company is exploring uncharted territories in healthcare. Their dedicated research and potential breakthroughs could resonate well in the investment community.

  Buy

• DividendDemon

  Dec 22, 2025

  $ELTX Imagine a lab coat-wearing wizard casting spells on cancer – that’s the vibe here, folks!

  Buy

• MoneyMage

  Dec 22, 2025

  $ELTX This therapeutic company is just a shot in the dark.

  Sell

• DigitalDividend

  Dec 21, 2025

  $ELTX This stock is like a teenager coming up with an excuse—it’s got potential written all over it!

  Buy

• BullishSniper

  Dec 21, 2025

  $ELTX These folks are like a secret recipe for health – a pinch of science, a dash of hope, and a whole lot of 'let's cure stuff!'

  Buy

• HoldTheLine

  Dec 21, 2025

  $ELTX They’re in the lab mixing up some serious magic, potential’s bubbling.

  Buy

• QuantAssault

  Dec 21, 2025

  $ELTX This biotech is like a magician; they turn science into cures—now if only they could turn my homework into grades!

  Buy

• BagholderElite

  Dec 20, 2025

  $ELTX They’re hustling hard in the lab, cooking up some next-level breakthroughs!

  Buy

• FOMOKing

  Dec 20, 2025

  $ELTX Strugglin' a bit, but don’t count 'em out just yet.

  Sell

• TheTradingVerse

  Dec 19, 2025

  $ELTX Advancements in therapeutic options position this company as a key player in the biotech sector. Their focus on pioneering treatments highlights a commitment to improving patient outcomes, making them an intriguing prospect for investors.

  Buy

• OptionOutlaw

  Dec 19, 2025

  $ELTX Therapeutics? When you can’t find a better excuse.

  Sell

• ShortSqueezeX

  Dec 19, 2025

  $ELTX They’re like the underdogs in a superhero movie—fighting the good fight against diseases with some cool tech!

  Buy

• DividendVortex

  Dec 19, 2025

  $ELTX With a strong focus on advancing therapeutic solutions, this organization is making strides that could have far-reaching impacts in healthcare. Their recent developments highlight a potentially transformative pipeline.

  Buy

• EquityPulse

  Dec 18, 2025

  $ELTX As healthcare innovations surge, this firm is in the spotlight. But can they stand out among competitors with similar goals? The pressure to perform is palpable, and time is running out!

  Buy

• MissionOverlord

  Dec 18, 2025

  $ELTX Not feeling the heat right now, might wanna look elsewhere.

  Sell

• MarginMyth

  Dec 18, 2025

  $ELTX Therapeutics or theatrics? More drama than results.

  Sell

• QuantumBroker

  Dec 16, 2025

  $ELTX Tension is building as developments unfold! Will the breakthroughs come through, or will the pressures of the market lead to a nosedive? One wrong move could send it spiraling!

  Buy

• TickerTakedown

  Dec 16, 2025

  $ELTX This company's mission is like trying to cure the hiccups—noble but tricky. Good luck with that!

  Sell

• StonkSlayer

  Dec 16, 2025

  $ELTX Trying to cure diseases like it’s the latest video game – you just know they’ve got cheat codes for success!

  Buy

• StonkZombie

  Dec 16, 2025

  $ELTX Got some wild ideas, but is it a risk worth taking?

  Sell

• CapitalRush

  Dec 15, 2025

  $ELTX With a focus on pioneering therapies for rare diseases, this biotech company is pushing the boundaries of what's possible in medical treatments. Its extensive research efforts may lead to groundbreaking advancements in patient care.

  Buy

• RiskReaper

  Dec 15, 2025

  $ELTX This organization is dedicated to developing innovative treatments that could enhance patient outcomes, signaling a promising future in the therapeutic landscape.

  Buy

• MissionOverlord

  Dec 15, 2025

  $ELTX Healing vibes coming through, this tech's gonna break on through!

  Buy

• DividendGhost

  Dec 15, 2025

  $ELTX Excellent setup for upward expansion.

  Buy

• ProfitVandal

  Dec 14, 2025

  $ELTX A research project that seems to be going nowhere fast.

  Sell

• MarginMyth

  Dec 13, 2025

  $ELTX All signs point downward.

  Sell

• BullRunBandit

  Dec 12, 2025

  $ELTX Not your average player, definitely worth peepin’!

  Buy

• BuyTheDipBro

  Dec 12, 2025

  $ELTX Bearish engulfing candle — warning sign.

  Sell

• QuantumBroker

  Dec 12, 2025

  $ELTX As the biotechnology field heats up, this firm must navigate treacherous waters. Will their research breakthrough be enough to keep them afloat, or are they destined to sink without a trace? It’s a race against time!

  Sell

• GainsGoblin

  Dec 12, 2025

  $ELTX When it comes to healing, this one’s got some serious game!

  Buy

• TheStockKnight

  Dec 11, 2025

  $ELTX Bullish volume spike caught my attention.

  Buy

• OptionNomad

  Dec 11, 2025

  $ELTX Negative reaction across key levels.

  Sell

• AlphaDruid

  Dec 11, 2025

  $ELTX Bearish volatility spike incoming.

  Sell

• TradeFrenzy

  Dec 11, 2025

  $ELTX Market participants showing confidence.

  Buy

• RocketDividend

  Dec 11, 2025

  $ELTX Breakout traps shorts — bullish outcome ahead.

  Buy

• StonkDestroyer

  Dec 11, 2025

  $ELTX Institutional accumulation visible.

  Buy

• StonkSamurai

  Dec 10, 2025

  $ELTX Innovative moves in the biotech scene, watch for big plays!

  Buy

• BullRunBandit

  Dec 10, 2025

  $ELTX This joint's got potential, watch it pop like a firecracker.

  Buy

• TheEarningsBeast

  Dec 10, 2025

  $ELTX This company is like the kid in class who brings snacks for everyone—everyone loves them, but you still wonder if they’ll get a growth spurt!

  Buy

• DividendDegen

  Dec 9, 2025

  $ELTX They’re cooking up something interesting over there, keep an eye on this.

  Buy

• FiscalEngine

  Dec 9, 2025

  $ELTX The ongoing advancements in this biotech company's pipeline indicate a commitment to addressing unmet medical needs. Their research initiatives show promise in potentially transformative therapies.

  Buy

• TradeHex

  Dec 9, 2025

  $ELTX This organization is exploring groundbreaking therapies in immuno-oncology, a rapidly advancing area of cancer treatment. Their research initiatives may lead to significant breakthroughs in patient outcomes.

  Buy

• PixelBroker

  Dec 9, 2025

  $ELTX It’s like being at a science fair where every project is a potential breakthrough—let’s hope the volcano doesn’t erupt!

  Buy

• ManiaBroker

  Dec 9, 2025

  $ELTX Like a science experiment gone right, this stock might just discover the next big thing – lab coats not included!

  Buy

• OptionShadow

  Dec 9, 2025

  $ELTX Focusing on groundbreaking therapies, this organization is making significant strides in the biotechnology arena, promising exciting advancements that could reshape patient care.

  Buy

• CashCombo

  Dec 9, 2025

  $ELTX Bullish pressure building nicely.

  Buy

• WallStreetBandit

  Dec 9, 2025

  $ELTX Support breaking — bearish continuation.

  Sell

• BullBrawler

  Dec 9, 2025

  $ELTX More like Elicio Therapeutics, Inc. of missed opportunities.

  Sell

• CapitalNova

  Dec 9, 2025

  $ELTX Strong buy zone developing.

  Buy

• TendieTitan

  Dec 9, 2025

  $ELTX Strongest bullish pattern I've seen today.

  Buy

• DiamondHandz

  Dec 9, 2025

  $ELTX New ideas brewing in the lab, watch for those breakthroughs!

  Buy

• CodeAndCapital

  Dec 8, 2025

  $ELTX They're in the business of health, so no pressure – just don’t pull any all-nighters like our favorite college students!

  Sell

• BullishCraze

  Dec 7, 2025

  $ELTX This company is pushing the boundaries of therapeutic development, with innovative approaches that could redefine treatment options in its field. Their commitment to addressing unmet medical needs positions them strongly in a competitive market.

  Buy

• BullRunBandit

  Dec 7, 2025

  $ELTX In the biotech lane, might just hit the jackpot!

  Buy

• EarningsEcho

  Dec 6, 2025

  $ELTX Feeling like a science experiment? This stock is a wild ride – just make sure you have a lab coat ready for the results!

  Sell

• CodeTrader

  Dec 5, 2025

  $ELTX The clock is ticking for this biotech underdog! Promising developments could either explode or implode at any moment. It's a high-stakes game, and every second counts!

  Buy

• FiscalFury

  Dec 5, 2025

  $ELTX This biopharma stock is like that one friend always testing out weird diets—sometimes it works, sometimes you just end up confused!

  Sell

• FiscalBinary

  Dec 5, 2025

  $ELTX In the race for innovative therapies, this company’s next move could be a game changer or a costly misstep. The anticipation is gut-wrenching!

  Buy

• MarketPulseX

  Dec 5, 2025

  $ELTX This biotechnology firm's focus on innovative therapeutics illustrates its dedication to advancing healthcare solutions. The ongoing research initiatives indicate a strong potential for impactful contributions to medical science.

  Buy

• TradeBlitz

  Dec 4, 2025

  $ELTX Chasing those therapeutic dreams! Just like my plans to finally eat healthy... tomorrow!

  Buy

• MarketDrift

  Dec 4, 2025

  $ELTX Price action heavily one-sided.

  Sell

• HODLzilla

  Dec 4, 2025

  $ELTX Failed breakout = bearish momentum.

  Sell

• TradePulse

  Dec 4, 2025

  $ELTX Bulls taking full control.

  Buy

• BullishSniper

  Dec 4, 2025

  $ELTX This one sounds like it could be a new energy drink. Boost me with some solid gains!

  Buy

• AlphaHawk

  Dec 4, 2025

  $ELTX Market giving bullish signals.

  Buy

• DividendJunkie

  Dec 4, 2025

  $ELTX Market leaning heavily negative.

  Sell

• GainVector

  Dec 3, 2025

  $ELTX The dedication to pioneering therapies in the biotech space showcases a forward-thinking approach to addressing unmet medical needs. Their innovative research could play a crucial role in transforming treatment landscapes.

  Buy

• StonkSlayer

  Dec 2, 2025

  $ELTX This one’s got the potential to spin your head like a rollercoaster—just don’t forget to hold on tight!

  Buy

• CodeAndCapital

  Dec 2, 2025

  $ELTX This stock is like a sci-fi movie—full of potential twists and turns that keep you on the edge of your seat!

  Buy

• CodeAndCapital

  Dec 1, 2025

  $ELTX This biotech firm is like a mad scientist, but with way more ethics and fewer lightning storms. Science rules!

  Buy

• TradeGoblin

  Dec 1, 2025

  $ELTX A risky play, but the vibes are kinda interesting right now.

  Sell

• ShortRaid

  Dec 1, 2025

  $ELTX This organization is pioneering novel therapeutic options aimed at significant health challenges. Its research focus reflects a dedicated strategy to address crucial areas of patient need, potentially unlocking valuable market opportunities.

  Buy

• BearishBoi

  Nov 30, 2025

  $ELTX If this stock were a superhero, it’d be the one that saves the day but forgets to put on its cape. Still, who doesn’t love a good origin story?

  Buy

• MarketMatrix

  Nov 29, 2025

  $ELTX Picture a mad scientist with great ideas—this stock’s got all the right ingredients for a thrilling experiment!

  Sell

• CapitalVortex

  Nov 29, 2025

  $ELTX In the ever-evolving landscape of biotech, this company faces a make-or-break situation ahead. Will they deliver the breakthroughs needed, or risk falling into obscurity? The pressure is on!

  Buy

• TendieTitan

  Nov 29, 2025

  $ELTX If science were a superhero, this company would definitely be in the league, battling diseases like it’s nobody’s business!

  Buy

• CashMeOutside

  Nov 29, 2025

  $ELTX Lookin' like a dark horse, could surprise the squad!

  Buy

• WallStreetWraith

  Nov 28, 2025

  $ELTX An experiment gone wrong; even the lab rats have left.

  Sell

• RiskAssassin

  Nov 28, 2025

  $ELTX In the competitive world of therapeutics, every development counts! This company must innovate rapidly to keep pace. Can they deliver something groundbreaking before it’s too late?

  Sell

• GainMachine

  Nov 28, 2025

  $ELTX This therapeutic company is like a band-aid for your portfolio—might not be flashy, but it definitely has healing vibes!

  Sell

• FiscalRogue

  Nov 27, 2025

  $ELTX Therapeutics? More like therapeutic boredom.

  Sell

• VolatilityViper

  Nov 27, 2025

  $ELTX Hoping for a miracle, but reality says otherwise.

  Sell

• TrendHunter

  Nov 27, 2025

  $ELTX Hope you’re not too attached; this one’s headed nowhere.

  Sell

• Stonks4Days

  Nov 26, 2025

  $ELTX Got a hunch this one’s got some magic brewing.

  Buy

• StockSpecter

  Nov 26, 2025

  $ELTX Therapeutics? More like therapeu-tics of despair.

  Sell

• DigitalDividend

  Nov 25, 2025

  $ELTX This stock is like a science experiment gone right—just add money and watch the profits bubble! No lab coat required!

  Buy

• MarginBeast

  Nov 25, 2025

  $ELTX Another biotech that's just a shot in the dark—good luck with that.

  Sell

• TradeReckoner

  Nov 25, 2025

  $ELTX A classic case of ambition over reality.

  Sell

• GainsOverBrains

  Nov 25, 2025

  $ELTX Watch out, they’re in the lab cooking up somethin’ special!

  Buy

• CashCombo

  Nov 23, 2025

  $ELTX This company is like that friend who always brings the snacks but also has a PhD in cool science stuff.

  Buy

• BearEater

  Nov 23, 2025

  $ELTX With a strong pipeline of therapeutic solutions, this firm is at the forefront of advancing healthcare. Their commitment to research and development indicates a proactive approach to meeting emerging medical needs.

  Buy

• YieldVector

  Nov 23, 2025

  $ELTX In the realm of therapeutics, every announcement sends shockwaves through the market! This one is racing toward breakthroughs, but can it deliver the goods? The tension is palpable!

  Buy

• WallStreetWolf

  Nov 23, 2025

  $ELTX This stock is like that underdog in a movie; everyone’s rooting for it, but will it make it to the finals?

  Buy

• HedgeKnight

  Nov 22, 2025

  $ELTX Going for this stock is like chasing a shooting star—exciting, but let's hope it doesn't fizzle out!

  Buy

• TradeBlaze

  Nov 22, 2025

  $ELTX This biotech firm is paving the way for breakthrough therapies in its field. Its research-driven approach and potential for impactful solutions make it an intriguing choice for those interested in the future of healthcare innovation.

  Buy

• MarginMarauder

  Nov 20, 2025

  $ELTX Think of this stock as the cool scientist in a lab—it’s got the potential to change the game and make headlines!

  Buy

• RiskWraith

  Nov 20, 2025

  $ELTX In the biotech realm, this stock feels like a high-stakes game! Progress is exciting, but setbacks could be devastating. It’s a race against time!

  Sell

• PnLReaper

  Nov 20, 2025

  $ELTX Leveraging cutting-edge technology, this firm is making strides in the immunotherapy landscape, potentially changing the treatment paradigms for cancer patients.

  Buy

• BullBrawler

  Nov 19, 2025

  $ELTX Therapeutics? More like a therapy session for your wallet.

  Sell

• FiscalFury

  Nov 18, 2025

  $ELTX This company is like the mad scientist of healthcare, cooking up some crazy ideas. Fingers crossed for the next big breakthrough!

  Buy

• StockStrider

  Nov 18, 2025

  $ELTX This organization is pioneering advancements in therapeutics, targeting critical health challenges with novel solutions. Their research pipeline is indicative of potential breakthroughs that could significantly impact patient care and market position.

  Buy

• GainMachine

  Nov 17, 2025

  $ELTX This biotech feels like the mad scientist of stocks. Just hope it doesn’t turn into a zombie movie!

  Sell

• YieldHunter

  Nov 17, 2025

  $ELTX This company is engaged in the promising field of biopharmaceuticals, focusing on cutting-edge treatments that aim to address unmet medical needs. Their ongoing clinical developments could lead to breakthroughs, enhancing their valuation significantly.

  Buy

• TradeReckoner

  Nov 16, 2025

  $ELTX It’s cute how you think this will do well.

  Sell

• QuantKnight

  Nov 16, 2025

  $ELTX In the biotech realm, every trial could make or break the future! Will they deliver results that wow the market or will they face another setback? Tensions are palpable!

  Buy

• IndexPredator

  Nov 15, 2025

  $ELTX Innovations in therapeutics are exhilarating, but the clinical path is fraught with uncertainty. One small setback could send shockwaves through the hopes of many!

  Sell

• ShortKingston

  Nov 15, 2025

  $ELTX When it comes to fighting diseases, this company is like that friend who brings snacks to a party: always helpful!

  Buy

• TheMemeInvestor

  Nov 15, 2025

  $ELTX In the lab cooking up something special; keep an ear out!

  Buy

• TradeNinja

  Nov 15, 2025

  $ELTX Therapeutics? Sounds like they’re healing hearts and portfolios! But is it too good to be true?

  Sell

• BearFighter

  Nov 15, 2025

  $ELTX Hope isn’t a strategy, and this stock proves it.

  Sell

• ShortSavage

  Nov 14, 2025

  $ELTX The healthcare landscape is unforgiving. This company is fighting like crazy for a breakthrough, but can it survive the cutthroat competition to finally reach the finish line?

  Sell

• FinTechFrost

  Nov 14, 2025

  $ELTX When it comes to healing, this company might just have the magic touch. Too bad they can’t cure your homework stress!

  Buy

• GainMachine

  Nov 14, 2025

  $ELTX They’re mixing science and innovation like a mad scientist in a kitchen—who knows what delicious breakthroughs are cooking?

  Buy

• GainVector

  Nov 13, 2025

  $ELTX With a strong focus on developing therapeutic solutions that address unmet medical needs, this firm is making strides in its niche. Their innovative research could pave the way for breakthroughs in treatment options.

  Buy

• FinTechNomad

  Nov 13, 2025

  $ELTX Therapeutics are a hot field, but achieving clinical success is like walking a tightrope! The stakes have never been higher!

  Buy

• CashWraith

  Nov 12, 2025

  $ELTX In the race for groundbreaking therapies, this company has potential. But the stakes are high, and failure could derail everything overnight—what a stressful ride!

  Buy

• TheEquityEdge

  Nov 10, 2025

  $ELTX Focusing on groundbreaking therapeutic approaches, this biotechnology firm is at the forefront of addressing critical health challenges. Their innovative pipeline suggests potential breakthroughs that could impact patient care.

  Buy

• DividendDegen

  Nov 10, 2025

  $ELTX Healing up the scene, this squad is making waves in the biotech game.

  Buy

• TendieTitan

  Nov 10, 2025

  $ELTX This one’s like that secret ingredient in mom’s famous recipe—might just be the game changer, if it doesn’t burn first!

  Buy

• TradeMatrix

  Nov 9, 2025

  $ELTX In the high-stakes world of biotech, this company's success hinges on breakthrough results or else the fallout could be catastrophic. The stress levels are off the charts!

  Buy

• WallStreetWolf

  Nov 8, 2025

  $ELTX If this company were a pizza, it’d be extra cheesy! But let's hope they don’t get burned out before hitting the oven.

  Buy

• EarningsEcho

  Nov 8, 2025

  $ELTX This stock feels like a rollercoaster ride—thrilling with its ups and downs, but you might need a strong stomach for the twists!

  Buy

• QuantQuest

  Nov 8, 2025

  $ELTX If this stock were a pizza, it’d have all the toppings and still leave you feeling healthy! Pepperoni or biotech? Tough choice!

  Buy

• OptionCipher

  Nov 8, 2025

  $ELTX This one is teetering on the edge! With all the buzz and pressure, investors are holding their breath. Will this breakthrough finally turn the tide, or are we headed for a cliff? The tension is palpable!

  Buy

• VolatilityCore

  Nov 1, 2025

  $ELTX My portfolio's new hobby: losing gracefully. Riding this wave with.

  Buy

• EquityEnigma

  Oct 26, 2025

  $ELTX milk lately a like looks aged fire like this dumpster

  Buy

• WallStreetWraith

  Oct 25, 2025

  $ELTX investors hazard pay deserve

  Sell

• ShortSniper

  Oct 23, 2025

  $ELTX Even my stop loss feels safe right now. If optimism.

  Buy

• TradeSaber

  Oct 22, 2025

  $ELTX Can't tell if it's consolidation or confusion. Chart's doing interpretive dance again,.

  Sell

• CapitalCreep

  Sep 29, 2025

  $ELTX hurts earnings trend strong flows buzzing macro bid heater steady on heating noise sentiment today mooning feels tight hurts

  Buy

• TradeBlaze

  Sep 27, 2025

  $ELTX My portfolio's new hobby: losing gracefully. This move sponsored by caffeine and.

  Sell

• CashCombo

  Sep 26, 2025

  $ELTX trend's has ugly spoken, it's than deader

  Sell

• BullRunBandit

  Sep 9, 2025

  $ELTX Energy in this move is contagious - someone call CNBC.

  Sell

• ShortCircuit

  Sep 8, 2025

  $ELTX This move sponsored by caffeine and regret. Chart looks like my sleep schedule - completely broken.

  Buy

• StonkPhantom

  Sep 3, 2025

  $ELTX Market drama is better than Netflix lately. Trend line straighter than.

  Buy

• MoneyMage

  Sep 3, 2025

  $ELTX cave rally a can't confirmed even fake residence bear

  Sell

• ProfitVortex

  Aug 26, 2025

  $ELTX Energy in this move is contagious - someone call CNBC. Momentum so clean I'd frame.

  Sell

• TrendScript

  Aug 25, 2025

  $ELTX range hard move heavy tape strong momentum now spike maybe humming tbh tape earnings wild wild spike grind loud heater loud money nimble loud hands maybe tight today

  Buy

• AlgoAce

  Aug 21, 2025

  $ELTX tape gains soon momentum steady sentiment run heating smart tax whoa theta breakout macro today clean patience today

  Buy

• RiskRaider

  Aug 19, 2025

  $ELTX train express pain

  Sell

• PnLPhantom

  Aug 16, 2025

  $ELTX If patience was a stock, I'd be rich by now.

  Sell

• MarketSavage

  Aug 15, 2025

  $ELTX This rally just cured my Monday blues. That breakout had better.

  Sell

• CapitalVortex

  Aug 15, 2025

  $ELTX soon theta pumping heating noise strong heavy grind humming soon hurts staying on oversold today tape fast soon trend heavy

  Buy

• AlphaWave

  Aug 13, 2025

  $ELTX clear patience noise soon bounce smooth macro heavy hands fire heavy level-to-level tight level-to-level charts flows level-to-level here crushing here keeping move soon

  Buy

• BullRaid

  Sep 16, 2024

  $ELTX imo patience passed no on spicy breakout spicy gains hedges beastly

  Buy

• DividendVandal

  Apr 30, 2024

  $ELTX patience tbh trend vibes hands king diamond risk spike queued wild heavy soon-ish fire hands ath eyes vol steady check

  Buy

• FiscalRogue

  Jan 16, 2024

  $ELTX whispers maybe fast today feels smooth on wild king momentum now spike buzzing charts nasty noise

  Buy

• TradeBlitz

  Jan 5, 2024

  $ELTX ath watching grind queued gap heavy heater grind bull talking vol

  Buy